Rating Change
RBC Capital reiterated its Outperform rating on Krystal Biotech, Inc. (NASDAQ:KRYS) on November 03, 2026.
reiterateNASDAQ:KRYS
RBC Capital Reiterates Outperform Rating on Krystal Biotech, Inc. (KRYS)
RBC Capital reiterated its Outperform rating on Krystal Biotech, Inc. (NASDAQ:KRYS) on November 03, 2026.
At publication ·
What changed
Krystal Biotech, Inc. (NASDAQ:KRYS) · reiterate
- Firm
- RBC Capital
- Rating
- Outperform to Outperform
- Price at event
- $305.03
- Market capitalization
- $7.2B
At a glance
Key takeaways
- RBC Capital reiterated an Outperform rating on Krystal Biotech on November 3, 2026, as the healthcare stock trades at $305.03 with a $7.2B market capitalization.
Market Context
Krystal Biotech, Inc. operates in the Healthcare sector. The stock currently trades at $305.03 with a market capitalization of $7.2B. The stock has gained 48.0% over the past 52 weeks.
Analyst coverage from RBC Capital provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Krystal Biotech, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Krystal Biotech, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Nov 03, 2026 | RBC Capital | Outperform | N/A |
| Nov 03, 2026 | TD Cowen | Buy | N/A |
| Nov 03, 2026 | Citigroup | Buy | N/A |
| Oct 15, 2026 | HC Wainwright & Co. | Buy | N/A |
| Sep 24, 2026 | Goldman Sachs | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View KRYS Stock Page
Frequently Asked Questions
What does the Outperform rating mean for KRYS?
A rating of Outperform from RBC Capital reflects the analyst's outlook on Krystal Biotech, Inc. (NASDAQ:KRYS). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the KRYS forecast page.